Target List. During the Research Program Term, Pfizer shall set forth on Appendix E up to [***] Targets as potential Program Targets (the “Target List”). Pfizer shall have the right to request that a Target be added to the Target List or that a Target on the Target List be replaced by providing written notice to Archemix at any time during the Research Program Term for any Target for which the initiation of the Research Plan has not yet begun; provided, that, at no time shall there be more than [***] Targets on the Target List at any one time. Archemix shall accept or reject the proposed Target in accordance with Section 2.2.3, 2.2.4 and 2.2.5. During the Research Program Term, Archemix will use commercially reasonable efforts to inform Pfizer promptly in [***] if it [***]to [***] with a [***] with [***] to a [***]or [***] relating to [***] a [***] on the [***]. Our proposed redactions are consistent with SEC guidance we have received in the past
Target List. During the Research Term, Juno shall have the right to update the Target List, on a [***] basis (or more frequently as provided below following receipt of a Target Notification), by providing an updated Target List to the JRC, provided that the Target List may not exceed [***]tumor-associated antigens or proteins at any one time. During the Research Term, if Fate desires, either directly or with an Affiliate or Third Party collaborator to research, develop, use or commercialize any Modulators for the purposes of modulating the therapeutic properties of Engineered T-Cells targeting a tumor-associated antigen or protein which is not on the Target List, then Fate shall first notify and disclose to Juno in writing the tumor-associated antigen or protein (the “Target Notification”). Juno shall have a period of [***] days from receipt of the Target Notification to elect to add such tumor-associated antigen or protein to the Target List (and, correspondingly, remove tumor-associated antigens or proteins from the Target List, if necessary, so that the Target List shall not exceed [***] Targets at any one time) by providing an updated Target List to the JRC. If Juno does not add such tumor-associated antigen or protein to the Target List during such [***] day period, or if Juno removes a tumor-associated antigen or protein from the Target List when providing an updated Target List (including, for the avoidance of doubt, in connection with any update of the Target List by Juno as described above) (in each case, such antigen or protein, together with any variant, isoform or polymorphism of any such antigen or protein (except for any variant, isoform or polymorphism that may be separately included on the Target List), a “Declined Target”), Fate shall not have any obligations or restrictions, and Juno shall not have any rights, under this Agreement thereafter with respect to any Declined Target. A Declined Target [***]. At the end of the Research Term, all Targets on the Target List that have not been selected as Selected Targets in accordance with Section 2.8 shall automatically be deemed Declined Targets.
Target List. (a) Subject to the other terms of this Section 2.4, (i) the Rolling Target List will include up to ************* designated for Immunization in each two-consecutive Contract Year period, and ********************************* (all such Targets selected by Sanofi for the Rolling Target List pursuant to this Section 2.4 being referred to as “Sanofi Targets”). The Parties shall conduct a meeting of the JRC within ten (10) Business Days of the Effective Date (the “Special JRC Meeting”) to ***********************************. The Rolling Target List will be updated on an annual basis at a meeting of the JRC to be held in January of each Contract Year, commencing in 2010 and ending in 2017 (the “Annual Draft Meeting”). At least thirty (30) days prior to the Annual Draft Meeting to be held in 2017, Regeneron shall provide to Sanofi information on the identity and status of Targets validated by Regeneron under the Discovery Program that were not previously selected as Targets on to the Rolling Target List. Targets on the Rolling Target List are progressed from the Rolling Target List to the Immunized Target List at commencement of Immunization. Any Targets on the Rolling Target List which have not progressed to the Immunized Target List during a Contract Year shall remain on the Rolling Target List, subject to Sections 2.4(b), 2.4(c), and 2.8 below. At each Annual Draft Meeting, the Parties shall select Targets for the Available Slots to bring the total number of Targets on the Rolling Target List back to ********. At the Special JRC Meeting and each Annual Draft Meeting, the Parties shall alternate selecting Targets for the Available Slots on the Rolling Target List, with Sanofi designating first, Regeneron second and the process repeating until Sanofi has selected as many Targets as it desires up to *************************************. Regeneron shall designate all Targets for the Available Slots remaining after Sanofi’s selections pursuant to this Section 2.4(a). For clarity, an Excluded Target cannot be selected onto the Rolling Target List without the mutual consent of the Parties. All Targets selected by the Parties for the Rolling Target List pursuant to this Section 2.4 shall be identified by their HUGO name, if applicable.
Target List. The original list of targets for both the GTO and the SDTcontains those 16 active galax- ies from Raban et al.(2008), plus NGC 1068, which are well visible from Paranal (DEC < ∼ +25◦) and which were thought to be bright enough for MIDI observations (unresolved core flux Fcore > 0.35 Jy). Additionally, the prototypical Seyfert 1 galaxy NGC 4151 was included in the list. Because of its northerly position at DEC = +39◦ 24', the latter does not rise more than 26◦ (corresponding to an airmass of 2.3) above the horizon at the location of the VLTI (24◦ 40' S). Despite the difficulty to observe it from Paranal, it was also included in the list of GTO targets in view of (1) its importance as the nearest and brightest type 1 AGN and of (2) it being one of the two AGN observed by other interferometric instruments. In preparation for the MIDI observations, high resolution imaging in the near- infrared with NACO, the adaptive optics assisted multi mode instrument of the Very Large Telescope (Rousset et al. 2003; Xxxxxx et al. 2003), and in the mid-infrared with TIMMI2, the Thermal Infrared Multi-Mode Instrument 2(Ka¨ ufl et al. 2003), was carried out for most of the AGN in the target list. Essentially, all nuclei remain unresolved both in the near and mid-infrared. The results of the investigation with TIMMI2 are pub-
Target List. As of the Execution Date, the Parties have mutually agreed to include the Targets set forth on Schedule 3.3.1 for entry into the research collaboration (such schedule, the “Target List”). The Target List [***]. The Target List indicates each Target [***]. The Target List may be updated from time to time in accordance with the gatekeeper provisions set forth in Section 3.3.2 (Gatekeeper).
Target List. Only Targets set out on the Target List shall be eligible for selection as a Selected Target.
Target List. Only Targets set out on the Target List shall be eligible for selection as a Selected Target. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Target List. MLNM shall provide to OBI, for review by and consultation with OBI, a list of First Position Targets and Second Position Targets (collectively, the “Target List”) no later than [**] days following the Effective Date, which Target List shall be incorporated into the Co-Promotion Plan. The Target List shall include only health care professionals [**] or any other indications for the Product that are approved in the Co-Promotion Territory during the Co-Promotion Term. OBI shall bring to the attention of the Co-Promotion and Marketing Committee any prescribers of the Product known to OBI who are not MLNM Targets. MLNM may, in consultation with the Co-Promotion and Marketing Committee, update the Target List semi-annually during each calendar year or more frequently as determined by the Co-Promotion and Marketing Committee; provided, however, that a change in the identity of more than [**] percent ([**]%) of the First Position Targets or [**] percent ([**]%) of the Second Position Targets on the Target List shall require the mutual agreement of the Parties.
Target List. MLNM has provided OBI with a Target List per Section 2.2.1 of the Agreement. The Target List is attached to this Co-Promotion Plan as Appendix A.
Target List. Prior to the Launch Date, Xxxxxxx shall provide to Company, in electronic form, a list that sets forth: (x) the name of each Target to which the Sales Representatives will perform Details; and (y) the priority classification of each such Target (high, medium or low). Such list, as amended from time to time by Xxxxxxx, shall be the “Target List”. Xxxxxxx shall furnish with or as part of the Target List the claims data upon which the Target priority classification was based if (a) Xxxxxxx is able to obtain an agreement with the relevant Third Party to provide such data to Company and (b) the Parties agree on which Party will bear the costs of providing such data to Company.
